Beta-Blocker therapy for acute coronary syndrome and stable coronary artery disease: Current issues and outcomes

Manoj Kesarwani

Beta-Blocker therapy for acute coronary syndrome and stable coronary artery disease: Current issues and outcomes

Cardiovascular Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Beta-blocker therapy is critical in the management of coronary artery disease. Although its role is better defined in the management of acute myocardial infarction with areas of lingering controversy, β-blocker use in terms of cardiovascular outcomes in stable coronary artery disease is less understood. In this heterogenous population, important questions arise about what groups of patients benefit most from β-blockers and the appropriate duration of use.

Original language	English (US)
Title of host publication	Beta-Blockers
Subtitle of host publication	Physiological, Pharmacological and Therapeutic Implications
Publisher	Nova Science Publishers, Inc.
Pages	287-298
Number of pages	12
ISBN (Electronic)	9781536133127
ISBN (Print)	9781536133110
State	Published - Jan 1 2018

ASJC Scopus subject areas

Medicine(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

Fingerprint Dive into the research topics of 'Beta-Blocker therapy for acute coronary syndrome and stable coronary artery disease: Current issues and outcomes'. Together they form a unique fingerprint.

Cite this

@inbook{b24734f03c1c4a5cb441af61318f63ed,

title = "Beta-Blocker therapy for acute coronary syndrome and stable coronary artery disease: Current issues and outcomes",

abstract = "Beta-blocker therapy is critical in the management of coronary artery disease. Although its role is better defined in the management of acute myocardial infarction with areas of lingering controversy, β-blocker use in terms of cardiovascular outcomes in stable coronary artery disease is less understood. In this heterogenous population, important questions arise about what groups of patients benefit most from β-blockers and the appropriate duration of use.",

author = "Manoj Kesarwani",

year = "2018",

month = jan,

day = "1",

language = "English (US)",

isbn = "9781536133110",

pages = "287--298",

booktitle = "Beta-Blockers",

publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Beta-Blocker therapy for acute coronary syndrome and stable coronary artery disease

T2 - Current issues and outcomes

AU - Kesarwani, Manoj

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Beta-blocker therapy is critical in the management of coronary artery disease. Although its role is better defined in the management of acute myocardial infarction with areas of lingering controversy, β-blocker use in terms of cardiovascular outcomes in stable coronary artery disease is less understood. In this heterogenous population, important questions arise about what groups of patients benefit most from β-blockers and the appropriate duration of use.

AB - Beta-blocker therapy is critical in the management of coronary artery disease. Although its role is better defined in the management of acute myocardial infarction with areas of lingering controversy, β-blocker use in terms of cardiovascular outcomes in stable coronary artery disease is less understood. In this heterogenous population, important questions arise about what groups of patients benefit most from β-blockers and the appropriate duration of use.

UR - http://www.scopus.com/inward/record.url?scp=85048386885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048386885&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85048386885

SN - 9781536133110

SP - 287

EP - 298

BT - Beta-Blockers

PB - Nova Science Publishers, Inc.

ER -